Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Forward Industries rallied in morning trading after disclosing a record quarterly rise in its Solana treasury and a preliminary, unaudited net asset value of about $870 million as of September 30, 2026. The company ended the fiscal fourth quarter with 8,501,298 SOL-equivalent tokens, adding 948,601 SOL during the period at an average cost of $83 pe…
President Donald Trump is expected to designate Jay Clayton, the current Director of National Intelligence who supervises 18 agencies, as his principal adviser on artificial intelligence, according to Reuters and an earlier CBS report. The White House has not formally confirmed the choice. The potential appointment marks a departure from the presid…
Alphabet is executing on AI and cloud, generating strong free cash flow while its valuation has pulled in. With a market cap north of $4.1 trillion but a P/E near 16.8 and a healthy balance sheet, this trade targets a recovery toward the 52-week highs as AI revenue catalysts and large hyperscaler deals drive upside over the next 180 trading days.
Riley Exploration Permian (REPX) offers a conventional oil & gas exposure in the Permian Basin with a $907M market cap, low leverage, positive free cash flow and a 3.9% yield. Valuation is compelling (P/E ~7.7, EV/EBITDA ~3.9); technicals are neutral and short interest is nontrivial. Trade idea: long REPX at $41.10, target $48.00, stop $36.00 for a…
CRISPR Therapeutics announced it will present Phase 1 clinical data of zugocabtagene geleucel (zugo-cel), a CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy targeting CD19 for autoimmune diseases, at the American College of Rheumatology Convergence 2026. The therapy is under evaluation across rheumatologic, hematologic, and neurologic autoimmu…
The Baltic Exchange's dry bulk freight index rose modestly on Friday for a second consecutive session, propelled by gains in capesize vessel rates. Despite the daily uptick, the main index finished the week down 8.1%. Capesize earnings increased while panamax rates edged lower over the same period, leaving mixed signals across vessel classes.
Gold prices inched higher on Friday after weaker-than-expected U.S. jobs numbers raised the likelihood that the Federal Reserve will leave interest rates unchanged at its upcoming policy meeting. The metal remains on course for a second consecutive weekly loss, weighed by a strong U.S. dollar and elevated Treasury yields even as markets price in a …
Paramount Skydance Corp will drop its combined name and operate under the Skydance corporate identity once its $110 billion merger with Warner Bros. Discovery closes next week. CEO David Ellison says the change provides a unified parent company while maintaining the standalone prominence of Paramount and Warner Bros.; investors are focused on the o…
Northrop Grumman introduces FORTITUDE™, a patented multilayer gallium nitride chip technology that significantly advances data processing capabilities by delivering triple the power and twenty times better signal quality. Designed for satellites, radar, GPS, electronic warfare, and emerging 6G systems, FORTITUDE™ reduces component counts, weight, a…
Viking Holdings (VIK) pulled back from recent highs, creating a mid-term dip-buy opportunity. Solid Q2 results, high booking curves (96% for 2026) and fleet-driven revenue growth underpin margins that deserve a premium. Enter at $79.88, stop at $72.00 and target $112.00 over a 45-trading-day swing - asymmetric upside with a defendable stop.
Realty Income faces acute pressure from the bond market, but the business fundamentals - long-duration leases, tenant diversification, monthly payout discipline and active capital recycling - argue for a measured long trade. Targeting a rebound as rate volatility normalizes, this idea lays out entry, stop and target with clear timeframes and risk c…
SeaStar Medical announced that data evaluating the post-approval SAVE Registry results for their FDA-approved QUELIMMUNE (SCD-PED) device will be presented as a late-breaking poster at ASN Kidney Week 2026. The company focuses on treatments for critically ill patients with organ failure, especially pediatric acute kidney injury (AKI) due to sepsis.…
Meta's AI wins and strong FCF mask valuation and technical vulnerabilities. With a market cap near $1.87T, P/E around 27x, stretched technicals and rising short-volume in late September, we see a viable mid-term short opportunity. Entry $730.00, stop $757.00, target $660.00 over ~45 trading days.
Climb Bio, a clinical-stage biotechnology company, will present new clinical data for its investigational drugs CLYM116 and budoprutug targeting immune-mediated kidney diseases at the American Society of Nephrology Kidney Week 2026. The data includes preliminary Phase 1 results for CLYM116 in healthy volunteers and Phase 2 data for budoprutug in pr…
newcleo plc announced its first-half 2026 financial and operational results following its business combination and Nasdaq listing under ticker NWCL. The company raised approximately $247 million through the SPAC merger and PIPE financing, plus additional funds, totaling over $1 billion raised since inception. Key operational advances include major …
Vera Therapeutics announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in treating IgA nephropathy will be highlighted in a late-breaking oral presentation at ASN Kidney Week 2026. Additional interim data from the Phase 2 PIONEER trial in glomerular diseases will also be presented. TRUTAKNA is the first app…
Decent Holding Inc., a Nasdaq-listed company specializing in wastewater treatment and senior health services in China, announced the pricing of a $1.23 million follow-on offering involving 822,828 Class A ordinary shares and associated warrants. The proceeds will support working capital and general corporate purposes. The securities offering is exp…
Anthropic's potential $2 trillion IPO is headline-grabbing but not obviously frothy once you bake in rapid enterprise adoption, subscription pricing, and margin capture. This trade buys a measured long exposure with a clear stop to protect against execution or regulatory shocks.
AppLovin (APP) has taken a beating after disclosure of AI development delays and a sharp sell-off in August. Fundamentals still point to robust growth, premium margins and strong cash generation. With technical oversold signals, elevated short interest and FCF of roughly $4.53B against a ~$92B market cap, the market appears to be pricing in a worst…
Artiva Biotherapeutics announced multiple data presentations at the American College of Rheumatology (ACR) Convergence 2026, featuring updated clinical results on its AlloNK® cell therapy combined with rituximab for treating refractory rheumatoid arthritis and other autoimmune diseases. The company also plans to initiate a Phase 3 registrational tr…
Broadcom's headline-driven pullback tied to Anthropic noise is disproportionate to the company's cash generation, hyperscaler relationships, and AI networking momentum. Valuation is elevated, but free cash flow and locked-in AI commitments give downside protection and upside on a normalization of sentiment.
Cuprina Holdings (Nasdaq: CUPR) announced it will acquire East Coast Podiatry and Orchard Clinic, a Singapore healthcare group operating seven clinics with FY2025 revenue of approximately S$9.1 million and EBITDA of S$1.2 million. The acquisition for about S$4 million (US$3.1 million) includes cash and company shares subject to lock-up and is expec…
Hall Chadwick Acquisition Corp. (NASDAQ: HCAC) and REEcycle Holdings, Inc. have jointly filed a registration statement on Form S-4 with the SEC relating to their proposed business combination. The filing includes a preliminary proxy statement/prospectus for shareholder approval and outlines next steps in the transaction process including mailing de…
Evaxion A/S, a clinical-stage TechBio company listed on NASDAQ, will present new immune data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting. The data highlight systemic immunomodulatory effects and durable clinical responses in advanced melanoma patients, foll…
ATA Creativity Global announced that it received a bid deficiency notice from Nasdaq due to its American Depositary Shares trading below the minimum required price of $1.00 for 31 consecutive business days. The company has until March 29, 2027, to regain compliance by raising its share price above $1.00 for 10 consecutive days. If not, it may seek …
